

Figure S1. (A) Grade 1-3 patient survival based on low staining (\leq median h-score) and high staining ($>$ median h-score). Cases with low sortilin h-score had longer median survival (36.5 months) compared to high sortilin h-score (23.5 months). (B) GBM patient survival based on low staining (\leq median h-score) and high staining ($>$ median h-score). Cases with low sortilin h-score had longer median survival (12.5 months) compared to high sortilin h-score (11 months).




Figure S2. (A) Grade 1-3 patient survival based on low (\leq median) and high ($>$ median) sortilin concentration in plasma. Cases with low sortilin concentration had longer median survival (35 months) compared to high sortilin concentration (25 months). (B) GBM patient survival based on low (\leq median) and high ($>$ median) concentration in plasma. Cases with low sortilin concentration had longer median survival (12 months) compared to high sortilin concentration (10 months).




Figure S3. A) Correlation of sortilin in tissue cytonuclear H-score and soluble sortilin in plasma concentration. **B)** Correlation of high sortilin expression in tissue cytonuclear H-score and high soluble sortilin concentration in plasma.




Figure S4. Densitometric analysis of sortilin protein intensity by subgroups. CL = classic, MES = Messenchymal, PN = Proneural. * $P < 0.05$, ** $P < 0.01$, Student's t-test or ANOVA.




Figure S5. Viability assay Cell lines treated with AF38469 MGMT methylated v's MGMT unmethylated.